Passage Bio
PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced the appointment of William Chou, M.D. as chief executive officer (CEO) and a member of the board, effective immediately. Edgar B. (Chip) Cale will resign his position as the companys interim CEO and will continue in his role as general counsel and corporate secretary. Maxine Gowen, Ph.D., will step down as interim executive chairwoman following a brief transition period and will then continue to serve as chairwoman.
The Board and I are delighted to welcome Will to Passage Bio to lead the company through an exciting phase of development, said Dr. Gowen. Wills depth of experience and success in developing and commercializing advanced therapeutics will be instrumental in establishing and solidifying the company as a leader in genetic medicines.
Dr. Chou is an accomplished executive with nearly twenty years of healthcare experience across a range of development and commercialization roles. Most recently, Dr. Chou served as CEO of Aruvant Sciences, a clinical-stage biopharmaceutical company focused on developing gene therapies for rare diseases.
I am thrilled to join the talented team at Passage Bio and build upon the companys many accomplishments and impressive capabilities, said Dr. Chou. With three ongoing clinical programs, we are poised to deliver multiple meaningful milestones over the coming quarters. As a clinician, it is my privilege to lead a company with tremendous potential to bring transformative therapies to patients with CNS disorders for which there are limited or no approved treatment options today.
Prior to joining Aruvant, Dr. Chou served in a variety of leadership roles at Novartis, including vice president, global disease lead for Novartis Cell and Gene Therapy unit where he oversaw the global commercial launch of Kymriah, the first CAR-T cell therapy. Prior to that role, Dr. Chou led the Kymriah lymphoma clinical development program to approvals in the United States, Europe, Australia, Canada and Japan. Before joining Novartis, Dr. Chou worked at the Boston Consulting Group where he focused on commercial and clinical pharmaceutical strategy.
Story continues
Dr. Chou holds an M.B.A. from the Yale School of Management, an M.D. from the University of Pittsburgh School of Medicine, and an A.B. in politics and economics from Princeton University. Dr. Chou completed his residency in internal medicine at Yale New Haven Hospital and his fellowship in geriatrics at Yale University.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical-stage genetic medicines company on a mission to provide life-transforming therapies for patients with CNS diseases with limited or no approved treatment options. Our portfolio spans pediatric and adult CNS indications, and we are currently advancing three clinical programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia with several additional programs in preclinical development. Based in Philadelphia, PA, our company has established a strategic collaboration and licensing agreement with the renowned University of Pennsylvanias Gene Therapy Program to conduct our discovery and IND-enabling preclinical work. Through this collaboration, we have enhanced access to a broad portfolio of gene therapy candidates and future gene therapy innovations that we then pair with our deep clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies. More information is available at http://www.passagebio.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, including, but not limited to: our expectations about timing and execution of anticipated milestones, including initiation of clinical trials and the availability of clinical data from such trials; our expectations about our collaborators and partners ability to execute key initiatives; our expectations about manufacturing plans and strategies; our expectations about cash runway; and the ability of our lead product candidates to treat their respective target monogenic CNS disorders. These forward-looking statements may be accompanied by such words as aim, anticipate, believe, could, estimate, expect, forecast, goal, intend, may, might, plan, potential, possible, will, would, and other words and terms of similar meaning. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including: our ability to develop and obtain regulatory approval for our product candidates; the timing and results of preclinical studies and clinical trials; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events; the risk that positive results in a preclinical study or clinical trial may not be replicated in subsequent trials or success in early stage clinical trials may not be predictive of results in later stage clinical trials; failure to protect and enforce our intellectual property, and other proprietary rights; our dependence on collaborators and other third parties for the development and manufacture of product candidates and other aspects of our business, which are outside of our full control; risks associated with current and potential delays, work stoppages, or supply chain disruptions caused by the coronavirus pandemic; and the other risks and uncertainties that are described in the Risk Factors section in documents the company files from time to time with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. Passage Bio undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
For further information, please contact:
Passage Bio Investors:Stuart HendersonPassage Bio267-866-0114shenderson@passagebio.com
Passage Bio Media:Mike BeyerSam Brown Inc. Healthcare Communications312-961-2502MikeBeyer@sambrown.com
Read the original post:
Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer - Yahoo Finance
- CRISPR: A game-changing genetic engineering technique - January 4th, 2023
- Genetic Counseling Online Course - School of Medicine Columbia ... - January 4th, 2023
- Genetics & Medicine - Site Guide - NCBI - National Center for ... - December 27th, 2022
- Lilly, ProQR to expand genetic medicine development agreement - December 27th, 2022
- Central Dogma and Genetic Medicine - HHMI BioInteractive - November 24th, 2022
- Social, Environmental, Cognitive, and Genetic Influences on the Use of ... - November 24th, 2022
- Genetically modified food controversies - Wikipedia - October 29th, 2022
- BSGM - The British Society for Genetic Medicine - October 13th, 2022
- Genetic and Genomic Medicine - Nationwide Children's Hospital - October 13th, 2022
- Carrier Screening for Genetic Conditions | ACOG - October 13th, 2022
- New NHS genetic testing service could save thousands of children in England - The Guardian - October 13th, 2022
- Vertex, after setbacks, moves forward with second-generation rare disease drug - BioPharma Dive - October 13th, 2022
- Metagenomi Announces Participation in October Investor and Industry Conferences - Business Wire - October 4th, 2022
- NovaSeq X machines will make genetic analysis even faster and cheaper - Mezha.Media - October 4th, 2022
- ORYZON to Give Updates on Corporate Progress in October - BioSpace - October 4th, 2022
- e-therapeutics: Fundraise of 13.5 million - BioSpace - October 4th, 2022
- The inheritance of hope curing genetic heart disease now within grasp - British Heart Foundation - October 4th, 2022
- MS Genetic Counseling | Ohio State College of Medicine - September 16th, 2022
- Genetic Counselor - Mayo Clinic College of Medicine & Science - September 16th, 2022
- UCLA researcher awarded National Academy of Medicine prize for work on genetics of autism - Newswise - September 16th, 2022
- Medical research doesn't serve everyone. This effort hopes to build one of the most diverse health databases ever - Colorado Public Radio - September 16th, 2022
- Precision Medicine Offers Hope for More Targeted Rash Diagnosis and Treatment - Dermatology Times - September 16th, 2022
- Redmond firefighters to 'Fill the Boot' for Muscular Dystrophy Association - KTVZ - September 16th, 2022
- Why Monkeypox Wasnt Another COVID-19 - FiveThirtyEight - September 16th, 2022
- Endometriosis Researchers One Step Closer to Diagnosing Condition With Menstrual Blood - Business Wire - September 16th, 2022
- The Biggest CGT Breakthroughs Through the Eyes of Our 2022 Power List - The Medicine Maker - September 16th, 2022
- Humans evolved with their microbiomes like genes, your gut microbes pass from one generation to the next - The Conversation - September 16th, 2022
- When to Use Targeted Therapy for Iodine-Refractory Thyroid Cancer - Targeted Oncology - September 16th, 2022
- Gracell Biotechnologies to Participate in Three Upcoming Investor Conferences - PR Newswire - September 16th, 2022
- CRISPR is 10: A decade of gene editing refinements presents new ways to address agricultural diseases thought to be incurable - Genetic Literacy... - September 16th, 2022
- Sarepta Therapeutics Announces Recipients of Route 79, The Duchenne Scholarship Program, for ... - The Bakersfield Californian - September 8th, 2022
- 'Record' Gains in Bringing Research Closer to the Patient - Applied Clinical Trials Online - September 8th, 2022
- Metagenomi Announces Participation in September Investor and Industry Conferences - Business Wire - September 8th, 2022
- Sarepta Therapeutics Announces That FDA has Lifted its Clinical Hold on SRP-5051 for the Treatment of Duchenne Muscular Dystrophy - Yahoo Finance - September 8th, 2022
- Studies Reveal Aggressive Prostate Cancer Linked to Ancestral Heritage - DocWire News - September 8th, 2022
- Lonza and Touchlight collaboration will expands customer's access to DNA - Labiotech.eu - September 8th, 2022
- Genetic variants in miR-145 gene are associated with the risk of asthma in Taiwan | Scientific Reports - Nature.com - September 8th, 2022
- Elderly are more affected by COVID brain fog, but 'cognitive rehab' could be an effective treatment - Genetic Literacy Project - September 8th, 2022
- A therapy found to improve cognitive function in patients with Down syndrome - EurekAlert - September 8th, 2022
- Ovid turns to gene therapy startup to restock drug pipeline - BioPharma Dive - August 30th, 2022
- Morris Animal Foundation Golden Retriever Lifetime Study Celebrates 10 Years - PR Newswire - August 30th, 2022
- Immortal jellyfish genes identified that may explain their long lives - New Scientist - August 30th, 2022
- Walk Again Or Stop Blindness. How Gene Therapy Is Revolutionizing Medicine - Nation World News - August 30th, 2022
- ElevateBio and the University of Pittsburgh Announce Creation of Pitt BioForge BioManufacturing Center at Hazelwood Green to Accelerate Cell and Gene... - August 30th, 2022
- Therapeutic Effects of Tretinoin | JIR - Dove Medical Press - August 30th, 2022
- Physical Activity May Have a Stronger Role than Genes in Longevity - Newswise - August 30th, 2022
- BridgeBio, Baylor College of Medicine to Collaborate on Genetic Disease ... - August 22nd, 2022
- New $2.8-million gene therapy becomes most expensive medicine in history - New Atlas - August 22nd, 2022
- Molecular Map Reveals Insights Into the Genetic Drivers of CLL - The ASCO Post - August 22nd, 2022
- Biopharmaceutical Company Expands Clinical Trials On Texas A&M-Developed Angelman Syndrome Treatment - Texas A&M University Today - August 22nd, 2022
- Restrictive abortion laws are limiting the options parents have after receiving genetic test results, experts say - Yahoo News - August 22nd, 2022
- Marketing and Industry Trends Influencing Precision Medicine in 2022 - Healthcare Tech Outlook - August 22nd, 2022
- expert reaction to study investigating use of genetic risk score for prostate cancer in men with lower urinary tract symptoms to predict diagnosis -... - August 22nd, 2022
- As the Smithsonian wraps a genome exhibit, leaders in the field reflect - STAT - August 22nd, 2022
- Why some people suffer more from COVID-19 than others - EurekAlert - August 22nd, 2022
- Q3 2022 Earnings Forecast for LogicBio Therapeutics, Inc. Issued By William Blair (NASDAQ:LOGC) - Defense World - August 22nd, 2022
- Next generation patient avatars: Expanding the possibilities with MicroOrganospheres - EurekAlert - August 22nd, 2022
- Masters Program in Genetic Counseling - Perelman School of Medicine at ... - August 14th, 2022
- Admissions | Master's Program in Human Genetics & Genetic Counseling ... - August 14th, 2022
- The Silver Lining Of Innovation in Genetic Medicine - Pharmaceutical Executive - August 14th, 2022
- Genetics Team Serves as Go-to for Mom of Son With Extremely Rare Disorder - Stanford Medicine Children's Health Blog - Stanford Children's Health - August 14th, 2022
- UI professor receives grant from National Institutes of Health - Iowa Now - August 14th, 2022
- Lilly's Taltz (ixekizumab) Now Available in New, Citrate-Free Formulation to Reduce Injection Site Pain for Improved Patient Experience - PR Newswire - August 14th, 2022
- Research Roundup: 21 Genes Linked to Increased Risk of Alzheimer's and More - BioSpace - August 14th, 2022
- Personalised medicine made in hospitals can revolutionise the way diseases are treated the challenge now will be implementing it - The Conversation... - August 14th, 2022
- Beyond Paxlovid for covid-19: The hunt for better covid medications - Grid - August 14th, 2022
- PVM to Play Role in Research on New Patent-pending Method to Mass-produce Antitumor Cells to Treat Blood Diseases and Cancer - Purdue University - August 14th, 2022
- Analyzing Kiromic BioPharma (NASDAQ:KRBP) and LogicBio Therapeutics (NASDAQ:LOGC) - Defense World - August 14th, 2022
- Corporate America's Abortion Radicalism - The American Conservative - August 14th, 2022
- A team of Oxford and Mexican researchers want to diversify genomic databases. Can they end 'parachute science,' too? - STAT - August 14th, 2022
- The aging heart accumulates mutations while losing the ability to repair them - EurekAlert - August 14th, 2022
- Generation Bio Reports Business Highlights and Second Quarter 2022 Financial Results - GuruFocus.com - August 5th, 2022
- Population Genetic Testing: Save Lives And Money, While Avoiding Financial Toxicity - Forbes - August 5th, 2022
- Genetic Counselors Scramble Post- Roe to Provide Routine Pregnancy Services without Being Accused of a Crime - Scientific American - August 5th, 2022
- GENERATION BIO CO. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) - Marketscreener.com - August 5th, 2022
- Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results - Yahoo Finance - August 5th, 2022
- Researchers discover one of the largest known bacteria-to-animal gene transfer inside a fruit fly - EurekAlert - August 5th, 2022
- Intellia Therapeutics Announces Second Quarter 2022 Financial Results and Highlights Recent Company Progress - Yahoo Finance - August 5th, 2022
- Medical Student's Crime In Cipolletti: They Found A Man's DNA Under The Victim's Thumb - Nation World News - August 5th, 2022
- A new era: After winding path and safety scares, gene therapy enters the clinic - Sydney Morning Herald - August 5th, 2022